ViaCyte, Inc.

141 articles about ViaCyte, Inc.

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Cavendish Global Health Impact Forum

  5/11/2015

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At ARM's Third Annual Regen Med Investor Day

  3/17/2015

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At JDRF TypeOneNation Research Summit

  3/3/2015

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At 35th Annual Cowen and Company Health Care Conference

  2/25/2015

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Two San Diego Events: Biocom's Global Life Science Partnering Conference And University of California, San Diego (UCSD) Diabetes Public Forum

  2/23/2015

• A Pancreas In A Capsule, ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Reveals

  2/13/2015

• JDRF Honors Current and Former ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Team With Top Scientific Excellence Award

  1/12/2015

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial

  1/8/2015

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Biotech Showcase In San Francisco

  12/22/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes

  12/18/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At 26th Annual Piper Jaffray Healthcare Conference

  11/20/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives U.S. Patent Claiming Alternative Methods to Manufacture Pancreatic Progenitor Cells In Vitro

  11/6/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.)'s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted Into First Patient

  10/29/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Upcoming Stem Cell Meeting On The Mesa Conference

  10/6/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Awarded $16.6 Million Accelerated Development Pathway Grant From California Institute for Regenerative Medicine

  9/11/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Gains $20 Million Through Deal With Janssen Research & Development

  8/22/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces FDA Acceptance Of IND To Commence Clinical Trial Of VC-01™ Candidate Cell Replacement Therapy For Type 1 Diabetes

  8/19/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Scores $5.4 Million Private Financing

  8/8/2014

• ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Files Investigational New Drug Application And Device Master File With FDA For Novel Cell Replacement Therapy Product Candidate Designed To Treat Patients With Type 1 Diabetes

  7/17/2014

• Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes

  7/17/2014